NanoVibronix Crecimiento futuro

Future controles de criterios 0/6

Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de NanoVibronix.

Información clave

n/a

Tasa de crecimiento de los beneficios

n/a

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Medical Equipment	17.1%
Tasa de crecimiento de los ingresos	n/a
Rentabilidad financiera futura	n/a
Cobertura de analistas	None
Última actualización	n/a

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Most Shareholders Will Probably Find That The Compensation For NanoVibronix, Inc.'s (NASDAQ:NAOV) CEO Is Reasonable

Dec 09

NanoVibronix receives extension to satisfy Nasdaq bid price requirement

Oct 19

NanoVibronix rises 27% on approval of Uroshield for sale in UK by NHS internal supply chain contract

Sep 23

NanoVibronix announces expansion of distribution pact for its ultrasound devices

Dec 11

NanoVibronix secures $6M in equity capital

Dec 02

NanoVibronix reports Q3 results

Nov 17

En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como NanoVibronix no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.

Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:NAOV - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2024	3	-3	-2	-2	N/A
6/30/2024	3	-3	-2	-2	N/A
3/31/2024	3	-3	-3	-3	N/A
12/31/2023	2	-4	-4	-4	N/A
9/30/2023	1	-5	-4	-4	N/A
6/30/2023	1	-5	-6	-6	N/A
3/31/2023	1	-5	-6	-6	N/A
12/31/2022	1	-5	-7	-7	N/A
9/30/2022	2	-6	-7	-7	N/A
6/30/2022	2	-12	-5	-5	N/A
3/31/2022	2	-10	-5	-5	N/A
12/31/2021	2	-14	-4	-4	N/A
9/30/2021	1	-13	-5	-5	N/A
6/30/2021	1	-7	-5	-5	N/A
3/31/2021	1	-8	-3	-3	N/A
12/31/2020	1	-4	-3	-3	N/A
9/30/2020	1	-5	-3	-3	N/A
6/30/2020	1	-4	-4	-4	N/A
3/31/2020	1	-4	-4	-4	N/A
12/31/2019	1	-6	-4	-4	N/A
9/30/2019	0	-6	-4	-4	N/A
6/30/2019	0	-6	-3	-3	N/A
3/31/2019	0	-6	-4	-4	N/A
12/31/2018	0	-4	-4	-4	N/A
9/30/2018	0	-5	-3	-3	N/A
6/30/2018	0	-5	N/A	-3	N/A
3/31/2018	0	-6	N/A	-3	N/A
12/31/2017	0	-6	N/A	-2	N/A
9/30/2017	0	-5	N/A	-2	N/A
6/30/2017	0	-4	N/A	-2	N/A
3/31/2017	0	-3	N/A	-2	N/A
12/31/2016	0	-3	N/A	-2	N/A
9/30/2016	0	-2	N/A	-1	N/A
6/30/2016	0	-3	N/A	-1	N/A
3/31/2016	0	-3	N/A	-2	N/A
12/31/2015	0	-3	N/A	-1	N/A
9/30/2015	0	-3	N/A	-1	N/A
6/30/2015	0	-3	N/A	-1	N/A
3/31/2015	0	-3	N/A	-1	N/A
12/31/2014	0	-3	N/A	-1	N/A
9/30/2014	0	-2	N/A	-1	N/A
6/30/2014	0	-2	N/A	-1	N/A
3/31/2014	0	-2	N/A	-1	N/A
12/31/2013	0	-2	N/A	-1	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de NAOV es superior a la tasa de ahorro (2.6%).

Beneficios vs. Mercado: Datos insuficientes para determinar si se prevé que los beneficios de NAOV crezcan más rápidamente que el mercado US

Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de NAOV crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de NAOV crezcan más rápidamente que el mercado de US.

Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de NAOV crezcan a un ritmo superior a 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de NAOV se prevé que sea elevada dentro de 3 años.

NanoVibronix Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Third quarter 2024 earnings released: US$0.36 loss per share (vs US$0.42 loss in 3Q 2023)

Nasdaq Notifies NanoVibronix Regarding Potential Delisting Due to Non-Compliance with Nasdaq Listing Rule 5550(a)(2)

NanoVibronix, Inc., Annual General Meeting, Dec 19, 2024

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.65 loss in 2Q 2023)

Insufficient new directors

NanoVibronix, Inc. Announces Commencement of UroShield Clinical Study at the University of Michigan

NanoVibronix Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(a)(2)

NanoVibronix, Inc. announced delayed annual 10-K filing

NanoVibronix Regains Nasdaq Compliance

Third quarter 2023 earnings released: US$0.42 loss per share (vs US$0.68 loss in 3Q 2022)

NanoVibronix, Inc. Gains Approval for Inclusion of UroShield Products in NHS Prescription Services' Drug Tariff

NanoVibronix, Inc. announced that it expects to receive $5 million in funding

NanoVibronix, Inc. Applies for Inclusion of Uroshield Products in Nhs Prescription Services' Drug Tariff

New minor risk - Share price stability

Second quarter 2023 earnings released: US$0.65 loss per share (vs US$0.93 loss in 2Q 2022)

NanoVibronix Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

First quarter 2023 earnings released: US$0.66 loss per share (vs US$0.81 loss in 1Q 2022)

Full year 2022 earnings released: US$3.84 loss per share (vs US$11.35 loss in FY 2021)

Most Shareholders Will Probably Find That The Compensation For NanoVibronix, Inc.'s (NASDAQ:NAOV) CEO Is Reasonable

NanoVibronix Receives FDA 510(k) Premarket Clearance for PainShield Plus

Nanovibronix, Inc. Announces Interim Results of Clinical Study for UroShield

Third quarter 2022 earnings released: US$0.034 loss per share (vs US$0.26 loss in 3Q 2021)

Insufficient new directors

NanoVibronix Receives Extension to Satisfy Nasdaq Price Requirement

NanoVibronix receives extension to satisfy Nasdaq bid price requirement

Insufficient new directors

NanoVibronix rises 27% on approval of Uroshield for sale in UK by NHS internal supply chain contract

NanoVibronix, Inc., Annual General Meeting, Sep 14, 2022

Will NanoVibronix (NASDAQ:NAOV) Spend Its Cash Wisely?

Insufficient new directors

Nanovibronix, Inc. Announces FDA 510(K) Submission for Painshield MD Plus

NanoVibronix, Inc. Adds Additional Product to Federal Supply Schedule

NanoVibronix, Inc. announced delayed annual 10-K filing

Will NanoVibronix (NASDAQ:NAOV) Spend Its Cash Wisely?

NanoVibronix Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

NanoVibronix Files Three U.S. Patent Applications Further Leveraging Its Innovative Surface Acoustic Wave Technology

NanoVibronix, Inc. Announces Positive Interim Results from Independent, Real World Patient Study of its UroShield

Is NanoVibronix (NASDAQ:NAOV) In A Good Position To Deliver On Growth Plans?

Third quarter 2021 earnings released: US$0.25 loss per share (vs US$0.099 loss in 3Q 2020)

NanoVibronix, Inc. Launches New, Transdermal Gel Containing Nano-Cannabidiol for the Treatment of Joint Pain and Reducing Inflammation

NanoVibronix: Portable Ultrasonic Therapeutic Devices

Second quarter 2021 earnings released: US$0.009 loss per share (vs US$0.20 loss in 2Q 2020)

NanoVibronix (NASDAQ:NAOV) Is In A Good Position To Deliver On Growth Plans

Nanovibronix, Inc Announces That the Therapeutic Goods Administration

Nanovibronix Announces Publication of Compelling Study Results for Uroshield in the Journal of Medical & Surgical Urology

NanoVibronix Receives Letter from the Listing Qualifications Department of the Nasdaq Stock Market

NanoVibronix, Inc. announced delayed 10-Q filing

NanoVibronix Receives Notice from Nasdaq for Not Complying with Continued Listing Rule

Nanovibronix Announces Expanded Cms Reimbursement Approval for Painshield

NanoVibronix, Inc. announced delayed annual 10-K filing

NanoVibronix UroShield Joins PainShield on Federal Supply Schedule, Expanding Access to VA Market

NanoVibronix Regains Nasdaq Compliance

NanoVibronix, Inc. Enters into an Amended and Restated Distribution Agreement

NanoVibronix, Inc. Amends and Expands Distribution Agreement for its Painshield and Painshield Plus with Ultra Pain Products, Inc

NanoVibronix announces expansion of distribution pact for its ultrasound devices

NanoVibronix, Inc Announces Independent Study Finds Significant Benefits Provided by UroShield Device

NanoVibronix secures $6M in equity capital

NanoVibronix reports Q3 results

Nanovibronix Expands Offerings with Introduction of Painshield Plus

NanoVibronix, Inc. Announces Executive Changes

NanoVibronix, Inc. has completed a Follow-on Equity Offering in the amount of $1.794783 million.

NanoVibronix's UroShield® Receives U.S. Food and Drug Administration Authorization for Entry into the US

NanoVibronix, Inc. has completed a Follow-on Equity Offering in the amount of $3.250001 million.

NanoVibronix, Inc. announced delayed 10-Q filing

NanoVibronix, Inc. announced that it has received $0.1 million in funding from Aigh Capital Management, LLC

NanoVibronix, Inc. announced that it has received $0.2 million in funding from Globis Capital Management, LLC

NanoVibronix, Inc. announced delayed 10-Q filing

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento